GoldenGolden
Advanced Search
Jason Kelly

Jason Kelly

Jason Kelly is the CEO and co-founder of Ginkgo Bioworks, a biotech company based in Boston, Massachusetts.

Jason Kelly is the CEO and co-founder of the biotech company Ginkgo Bioworks. He also co-founded Joyn Bio, a joint venture between Ginkgo Bioworks and Bayer.

Education

In 2003 Kelly received a Bachelor of Science degree in Chemical Engineering and Biology from the Massachusetts Institute of Technology (MIT). In 2008 he received a PhD in Biological Engineering, also from MIT.

Ginkgo Bioworks

Ginkgo Bioworks is a biotech company founded in 2008 in Boston, MA. Kelly is both a co-founder and the CEO of the company. Ginkgo engineers and manipulates microbes to use them for industrial and manufacturing purposes such as creating and replicating food flavors and fragrances.

In 2020, Ginkgo was one of many biotech companies to begin launching efforts against the COVID-19 pandemic. In March 2020, Ginkgo committed $25 million worth of free access to their organism foundry facility, where scientists can design and develop new biological designs, engineer cells, and bacterial strains in an effort to create a vaccine or diagnostic test. In November 2020, Ginkgo funded an expansion of a COVID-19 rapid antigen test manufacturing for the New Jersey company Access Bio. They secured 10 million testing kits for use by companies and organizations requiring regular tests to stay open.

Joyn Bio

Joyn Bio is a biotech company formed through a partnership between Ginkgo Bioworks and Bayer in 2017. Kelly is one of the company's co-founders and a board member. The company was founded in an effort to create alternative, environmentally friendly methods of typical agricultural practices in the food crop industry that threaten the global food supply and environment. These include such things like engineered microbes that allow cereal crops (corn, wheat, rice) to convert nitrogen from the air into a form of energy they can use to grow, preventing a reliance on chemical fertilizers.

Timeline

2017
Kelly founds Joyn Bio.
2008
Kelly founds Gingko Bioworks.
1981
Jason Kelly was born.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

⏰Synthetic Biology w/ Jason Kelly (CEO, Ginkgo Bioworks) On 👋 Clubhouse Podcast | 14 May 2021

May 14, 2021

CareTalk Podcast Episode #88 - Jason Kelly: Testing Our Way Out of the Pandemic

April 23, 2021

Jason Kelly of Ginkgo Bioworks, a Synthetic Biology Co. That's Starting a New Industrial Revolution

September 5, 2021

Companies

Company
CEO
Location
Products/Services

Ginkgo Bioworks

Jason Kelly

Boston, MA

Biotechnology

Joyn Bio

Mike Miille

Boston, MA

Biotechnology

News

Title
Author
Date
Publisher
Description
Emma Betuel
September 17, 2021
TechCrunch
Gingko Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Gingko's market debut is one of the largest in biotech history. It's expected to raise about $1.6 billion for the company. It's also one of the biggest SPAC deals done to date - Gingko [...]
Steve Lohr
September 16, 2021
www.nytimes.com
The story of Ginkgo Bioworks shows the challenges and progress in the emerging field of synthetic biology.
Steve Lohr
September 16, 2021
www.nytimes.com
The story of Ginkgo Bioworks shows the challenges and progress in the emerging field of synthetic biology.
Antonio Regalado
August 24, 2021
MIT Technology Review
Jason Kelly has promised a manufacturing revolution with DNA. Just don't ask him to make any products.
Allison DeAngelis
June 2, 2021
Business Insider
Ginkgo is going public via a SPAC at a $15 billion valuation. But it's pitching investors revenue growth beyond other synthetic-biology companies.
Jonathan Shieber
September 19, 2019
TechCrunch
Ginkgo Bioworks is now worth $4 billion after a $290 million capital infusion that will give the company the cash to dramatically expand its developer shop for genetic programming. The Boston-based company is one of a handful of U.S.-based early-stage companies that are on the forefront of developing the tools to modify genetic material for [...]
Lauren Johnson
September 16, 2019
Business Insider
Kambr plans to build revenue management software that big airlines can use to monitor how people buy airline flights.
Alexandra Semenova
Invalid Date
DealStreetAsia
Ginkgo's Motif Ingredients, which aims to replicate animal protein for meatless alternatives, is getting $90 million from Breakthrough Energy, others.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.